Table 1

 Clinical and demographic characteristics of the participants

NoAgeSexEyeAssociationsPresentation time (months)Baseline VAMonth 8 post-event VANeovascularisationShunts patent/attempted
F, female; M, male; L, left eye; R, right eye; HTN, hypertension; HCH, hypercholesterolemia; DM, diabetes mellitus; VA, visual acuity; HM, hand motion; LP, light perception; RD, retinal detachment.
Surgical group
176FLHTN, HCH4HM20/4001/4
265MRHCH620/60020/2002/4
376FRHTN, HCH, glaucoma420/600020/60002/3
434ML320/120020/2002/3, complicated by cataract
567FRDM, HCH, glaucoma5HM20/12002/3
670FR320/1200020/16001/4
765FLHTN220/400020/502/4
833ML220/120020/1001/2
965FRHTN, HCH420/1200HM1/3, complicated by RD
1070MRHTN, HCH3HM20/4001/3, complicated by vitreous cavity haemorrhage
Control group
1140ML120/32020/50
1250FRHTN120/1200HM
1370FRHTN320/600HM+
1479MLGlaucoma120/2400HM+
1565ML120/50020/320
1651MR120/320HM+
1765FLGlaucoma220/60020/4000
1869MLHCH120/120020/400
1953FRHTN120/40020/30
2060FRHTN120/600HM+
2151MRHTN, glaucoma120/400HM+
2259FLHTN120/60020/1000
2360MR320/40020/1200
2480MR120/1200LP+
2557MLHTN120/24020/100
2650FRHCH120/1200HM+
2736MLHTN220/24020/600
2870MLHCH, glaucoma120/40020/1200